Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CRNX |
---|---|---|
09:32 ET | 2776 | 45.88 |
09:34 ET | 100 | 45.88 |
09:36 ET | 100 | 46.13 |
09:38 ET | 350 | 45.96 |
09:39 ET | 1300 | 45.97 |
09:43 ET | 200 | 46.03 |
09:48 ET | 300 | 45.84 |
09:52 ET | 100 | 45.995 |
09:54 ET | 1141 | 45.86 |
09:56 ET | 400 | 45.87 |
09:57 ET | 4097 | 45.81 |
10:01 ET | 860 | 45.83 |
10:03 ET | 3869 | 46.05 |
10:06 ET | 1147 | 45.89 |
10:08 ET | 1165 | 45.96 |
10:10 ET | 500 | 46 |
10:15 ET | 1709 | 46.12 |
10:17 ET | 100 | 46.1315 |
10:19 ET | 1250 | 46.31 |
10:21 ET | 1100 | 46.2964 |
10:26 ET | 649 | 46.28 |
10:28 ET | 2000 | 46.49 |
10:30 ET | 200 | 46.47 |
10:32 ET | 2961 | 46.5 |
10:33 ET | 500 | 46.42 |
10:37 ET | 214 | 46.46 |
10:39 ET | 1300 | 46.26 |
10:42 ET | 300 | 46.22 |
10:44 ET | 100 | 46.19 |
10:46 ET | 100 | 46.235 |
10:48 ET | 1500 | 46.21 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Crinetics Pharmaceuticals Inc | 3.6B | -12.3x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
SpringWorks Therapeutics Inc | 3.0B | -8.2x | --- |
Dyne Therapeutics Inc | 3.0B | -8.0x | --- |
Nuvalent Inc | 4.3B | -27.1x | --- |
Merus NV | 3.2B | -20.6x | --- |
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its Paltusotine, an investigational, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. It has demonstrated pharmacologic proof-of-concept in a Phase 1 clinical study for CRN04894, an investigational, oral ACTH antagonist, that is in Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing's disease. Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.6B |
---|---|
Revenue (TTM) | $2.0M |
Shares Outstanding | 78.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.65 |
EPS | $-3.77 |
Book Value | $7.91 |
P/E Ratio | -12.3x |
Price/Sales (TTM) | 1,830.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -12,571.38% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.